2. Государственная стратегия противодействия распространению ВИЧ- инфекции в Российской Федерации на период до 2020 года и дальнейшую перспективу. Утверждена Распоряжением Правительства РФ от 20.10.2016 № 2203-р. http://government.ru/docs/24983/

[State strategy to counter the spread of HIV infection in the Russian Federation for the period up to 2020 and beyond. Approved by the Order of the Government of the Russian Federation dated 20.10.2016 № 2203-р]. (In Russ.). http://government.ru/docs/24983/

3. Уровень и структура лекарственной устойчивости ВИЧ среди наивных пациентов в Российской Федерации. Анализ Российской базы данных лекарственной устойчивости ВИЧ. www.hivresist.ru

[Level and structure of HIV drug resistance among naive patients in the Russian Federation. Analysis of the Russian HIV Drug Resistance Database]. (In Russ.). www.hivresist.ru

4. База данных лекарственной устойчивости ВИЧ Стэнфордского университета. https://hivdb.stanford.edu/dr-summary/resistance-notes/NRTI/#16Larder1995

[Stanford University HIV Drug Resistance Database]. (In Russ.). https://hivdb.stanford.edu/dr-summary/resistance-notes/ NRTI/#16Larder1995

5. Côté B., Burch J.D., Asante-Appiah E., Bayly Ch., Bédard L, Blouin M. еt al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse ranscriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg. Med. Chem. Lett. 2014; 24(3): 917–922. doi: 10.1016/j.bmcl.2013.12.070

6. Feng M., Sachs N.A., Xu M., Grobler J., Blair W., Hazuda D.J. et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016; 60(4): 2241–2247. doi: 10.1128/AAC.02650-15

7. Orkin C., Molina J.-M., Lombaard J., DeJesus E., Rodgers A., Kumar S. et al. Once-daily Doravirine in Human Immunodeficiency Virus Type 1–Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. Clin. Infect. Dis. 2020; 70(7): 1344–1352. doi: 10.1093/cid/ciz424

8. Johnson M., Kumar P., Molina J.-M., Rizzardini G., Cahn P., Bickel M. et al. for the DRIVE-SHIFT Study Group. Switching to Doravirine/Lamivudine/ Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J. Acquir. Immune Defic. Syndr. 2019; 81(4): 463–472. doi: 10.1097/QAI.0000000000002056

9. Wong A., Goldstein D., Mallolas J., DeJesus E., Johnson M., J.-M. Molina J.-M. et al. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. J. Acquir. Immune Defic. Syndr. 2019; 82(4): e47–e49. doi: 10.1097/QAI.0000000000002153

10. Soulie C., Santoro M.M., Charpentier C., Storto A., Paraskevis D., Di Carlo D. et al. Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients. J. Antimicrob. Chemother. 2019; 74(3): 614–617. DOI:10.1093/jac/dky464